Buehler, Sarah K. http://orcid.org/0009-0007-8467-7869
Lowther, Millie
Lukow, Paulina B.
Kirk, Peter A.
Pike, Alexandra C. http://orcid.org/0000-0003-1972-5530
Yamamori, Yumeya
Chavanne, Alice V. http://orcid.org/0000-0002-5860-2237
Gormley, Siobhan
Goble, Talya
Tuominen, Ella W.
Aylward, Jessica
McCloud, Tayla
Rodriguez-Sanchez, Julia
Robinson, Oliver J. http://orcid.org/0000-0002-3100-1132
Funding for this research was provided by:
RCUK | Biotechnology and Biological Sciences Research Council (BB/T008709/1)
Article History
Received: 18 January 2024
Accepted: 8 August 2024
First Online: 24 August 2024
Competing interests
: The authors declare the following competing interests: Oliver J. Robinson (O.J.R.) ran an investigator-initiated trial with medication donated by Lundbeck (escitalopram and placebo, no financial contribution). He also held an MRC-Proximity to discovery award with Roche and has completed consultancy work for Peak, IESO digital health, Roche and BlackThorn therapeutics. O.J.R. sat on the committee of the British Association of Psychopharmacology until 2022. All other authors declare no competing interests.